Definitive Healthcare Corp. (NASDAQ:DH) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Definitive Healthcare Corp. (NASDAQ:DH) by 209.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,209 shares of the company’s stock after buying an additional 10,977 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Definitive Healthcare were worth $161,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in Definitive Healthcare in the 3rd quarter worth $116,000. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in shares of Definitive Healthcare during the third quarter worth about $131,000. Arizona State Retirement System boosted its position in Definitive Healthcare by 13.6% in the fourth quarter. Arizona State Retirement System now owns 14,253 shares of the company’s stock valued at $142,000 after buying an additional 1,701 shares during the last quarter. Corton Capital Inc. increased its holdings in Definitive Healthcare by 17.0% in the 3rd quarter. Corton Capital Inc. now owns 19,964 shares of the company’s stock worth $160,000 after buying an additional 2,898 shares during the period. Finally, Bordeaux Wealth Advisors LLC acquired a new stake in Definitive Healthcare during the 3rd quarter valued at approximately $162,000. 98.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on DH. Canaccord Genuity Group cut their price objective on shares of Definitive Healthcare from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Definitive Healthcare in a report on Wednesday. Barclays boosted their price target on Definitive Healthcare from $10.00 to $11.00 and gave the company an “equal weight” rating in a report on Friday, March 1st. Stifel Nicolaus cut their target price on shares of Definitive Healthcare from $11.00 to $9.50 and set a “buy” rating for the company in a report on Wednesday. Finally, Morgan Stanley downgraded shares of Definitive Healthcare from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $11.50 to $9.00 in a report on Wednesday. Eight analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.81.

Definitive Healthcare Stock Performance

DH opened at $5.35 on Thursday. The company has a market cap of $630.18 million, a price-to-earnings ratio of -3.01, a PEG ratio of 6.12 and a beta of 1.41. The firm’s fifty day simple moving average is $7.70 and its two-hundred day simple moving average is $8.29. The company has a quick ratio of 2.31, a current ratio of 2.31 and a debt-to-equity ratio of 0.20. Definitive Healthcare Corp. has a 52-week low of $4.38 and a 52-week high of $12.45.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.02). Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. The firm had revenue of $65.93 million during the quarter, compared to analyst estimates of $66.01 million. Equities analysts anticipate that Definitive Healthcare Corp. will post 0.11 earnings per share for the current fiscal year.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.